Benzinga

Benzinga

Benzinga

domenica, settembre 06

Cytokinetics Inc

CYTKNASDAQ
Trade with Public
Trade with Public
$72.72
-1.23-1.66%
In chiusura: Sep 4, 5:00 PM EST
$72.72
N/A
Post-mercato: Sep 4, 4:00 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Cytokinetics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cytokinetics (CYTK).

Price Target Range — 9 Quarters

Analyst Consensus — 21 Analysts

3S.Buy
17Buy
1Hold
Consensus RatingBuy# Analysts21Avg. Consensus PT$99Upside to Avg. PT+36.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 31, 2026HC Wainwright & Co.Joseph PantginisMaintainedBuy$140
Aug 13, 2026BarclaysEmily FieldPT RaiseOverweight$95→$110
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $140 price target.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $110

Barclays analyst Emily Field maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $95 to $110.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $103

JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $97 to $103.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $112

Truist Securities analyst Srikripa Devarakonda maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $106 to $112.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $112

RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $117 to $112.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Cytokinetics, Raises Price Target to $110

Citizens analyst Jason N. Butler maintains Cytokinetics (NASDAQ:CYTK) with a Market Outperform and raises the price target from $105 to $110.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved